BIIB - Biogen Inc.
NEXT EARNINGS:
May 7, 2026
EPS Est: $3.05
|
Rev Est: $2.2B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$206.76
DETAILS
HIGH:
$250.00
LOW:
$143.00
MEDIAN:
$200.00
CONSENSUS:
$206.76
UPSIDE:
5.96%
Market Cap:
28.64B
Volume:
683,167
Avg Volume:
1,869,961
52 Week Range:
110.04-202.41
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.16
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
7,605
IPO Date:
1991-09-17
EPS (TTM):
8.85
P/E Ratio:
19.96
Revenue (TTM):
9.81B
Total Assets:
29.44B
Total Debt:
6.95B
Cash & Equiv:
3.01B
Rev Growth (5Y):
-6.1%
EPS Growth (5Y):
-18.7%
FCF Growth (5Y):
-11.6%
ROCE:
8.3%
Debt/Equity:
0.38
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-06 | $1.99 | $1.61 | +23.6% | $2.3B | $2.3B | +1.0% |
| 2025-10-30 | $4.81 | $3.88 | +24.0% | $2.5B | $2.3B | +4.9% |
| 2025-07-31 | $5.47 | $3.90 | +40.3% | $2.6B | $2.3B | +13.6% |
| 2025-05-01 | $3.02 | $2.90 | +4.1% | $2.4B | $2.2B | +8.8% |
| 2025-02-12 | $3.44 | $3.43 | +0.3% | $2.5B | $2.4B | +1.9% |
| 2024-10-30 | $4.08 | $3.77 | +8.2% | $2.5B | $2.4B | +1.3% |
| 2024-08-01 | $5.28 | $4.07 | +29.7% | $2.4B | $2.4B | -1.6% |
| 2024-04-24 | $3.67 | $3.47 | +5.8% | $2.2B | $2.3B | -4.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.81B | 9.68B | 9.84B | 10.17B | 10.98B | 13.44B | 14.38B | 13.45B | 12.27B | 11.45B | 10.76B | 9.70B |
| Net Income | 1.29B | 1.63B | 1.16B | 3.05B | 1.56B | 4.00B | 5.89B | 4.43B | 2.54B | 3.70B | 3.55B | 2.93B |
| EPS | 8.85 | 11.20 | 8.02 | 20.97 | 10.44 | 24.86 | 31.47 | 21.62 | 11.94 | 16.96 | 15.38 | 12.42 |
| Total Assets | 29.44B | 28.05B | 26.84B | 24.55B | 23.88B | 24.62B | 27.23B | 25.29B | 23.65B | 22.88B | 19.50B | 14.32B |
| Total Debt | 6.95B | 6.63B | 7.34B | 6.61B | 7.60B | 7.83B | 6.37B | 5.94B | 5.94B | 6.52B | 6.53B | 585.20M |
| Cash & Equivalents | 3.01B | 2.38B | 1.05B | 3.42B | 2.26B | 1.33B | 2.91B | 1.22B | 1.57B | 2.33B | 1.31B | 1.20B |
| Operating Cash Flow | 2.20B | 2.88B | 1.55B | 1.38B | 3.64B | 4.23B | 7.08B | 6.19B | 4.55B | 4.52B | 3.72B | 2.94B |
| Free Cash Flow | 2.05B | 2.52B | 1.24B | 1.14B | 3.38B | 3.81B | 6.56B | 5.30B | 3.68B | 3.86B | 3.07B | 2.63B |
| FCF per Share | 13.98 | 17.27 | 8.54 | 7.87 | 22.68 | 23.65 | 35.08 | 25.87 | 17.33 | 17.67 | 13.32 | 11.11 |
| Book Value | 18.26B | 16.72B | 14.80B | 13.40B | 10.90B | 10.70B | 13.34B | 13.04B | 12.61B | 12.14B | 9.37B | 10.81B |
| Cash & ST Investments | 3.82B | 2.38B | 1.05B | 4.89B | 3.80B | 2.61B | 4.48B | 3.54B | 3.69B | 4.90B | 3.43B | 1.85B |
| ROC Equity | 0.07 | 0.10 | 0.08 | 0.23 | 0.14 | 0.37 | 0.44 | 0.34 | 0.20 | 0.31 | 0.38 | 0.27 |